PriceTargets.com logo

Mainz Biomed - QUCY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$1.34 As of 09/11/2026 05:00 PM ET
▼ -0.03 (-2.19%)

This chart shows the closing price for QUCY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mainz Biomed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QUCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QUCY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Mainz Biomed in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.34.

This chart shows the closing price for QUCY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in Mainz Biomed. This rating has held steady since July 2026, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/18/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/16/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/15/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/13/2026
  • 1 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
8/12/2026
  • 1 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/11/2026

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/8/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
8/24/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
8/11/2026Zacks ResearchUpgradeHold
8/10/2026Litchfield Hills ResearchUpgradeStrong-Buy
8/7/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
5/11/2026Weiss RatingsUpgradeSell (E) ➝ Sell (E+)
4/27/2026Weiss RatingsDowngradeSell (E+) ➝ Sell (E)
3/12/2026Weiss RatingsInitiated CoverageSell (E+)
3/6/2026Maxim GroupDowngradeStrong-Buy ➝ Hold
(Data available from 9/11/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/13/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/15/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/14/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/14/2026
  • 0 very positive mentions
  • 27 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/13/2026
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/13/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/12/2026
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/11/2026

Current Sentiment

  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.

Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Read More

Today's Range

Now: $1.34
Low: $1.33
High: $1.40

50 Day Range

MA: $1.34
Low: $1.06
High: $1.60

52 Week Range

Now: $1.34
Low: $0.30
High: $4.93

Volume

322,885 shs

Average Volume

856,565 shs

Market Capitalization

$19.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Mainz Biomed?

The following equities research analysts have issued reports on Mainz Biomed in the last year: Litchfield Hills Research, Maxim Group, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for QUCY.

What is the current price target for Mainz Biomed?

0 Wall Street analysts have set twelve-month price targets for Mainz Biomed in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Mainz Biomed in the next year.
View the latest price targets for QUCY.

What is the current consensus analyst rating for Mainz Biomed?

Mainz Biomed currently has 1 sell rating, 2 hold ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in QUCY, but not buy more shares or sell existing shares.
View the latest ratings for QUCY.

What other companies compete with Mainz Biomed?

Other companies that are similar to Mainz Biomed include Momentus, Byrna Technologies, Vertical Aerospace, Optex Systems and Mobilicom. Learn More about companies similar to Mainz Biomed.

How do I contact Mainz Biomed's investor relations team?

Mainz Biomed's physical mailing address is ROBERT KOCH STRASSE 50, MAINZ, 2M, 55129. The company's listed phone number is 49 6131 5542860 and its investor relations email address is [email protected]. The official website for Mainz Biomed is mainzbiomed.com. Learn More about contacing Mainz Biomed investor relations.